Author: Willem van Lawick

Highlights to include antigenic and immunological characteristics of company’s unique stable prefusion F RSV subunit

Groningen, the Netherlands, November 19, 2015 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, today presents key characteristics of its unique prefusion F antigen, the core technology behind its lead product, SynGEM®, an intranasally delivered, needle-free vaccine for the prevention of respiratory syncytial virus (RSV). Data were presented at the RSV Vaccines for World conference (RSVVW), taking place at the Salk Institute in La Jolla, California. (more…)

Amsterdam, The Netherlands, November 3, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ has been selected by the American Society of Hematology (ASH) Program Committee for presentation at the 57th Annual Meeting in Orlando, Florida on December 7, 2015.
The abstract provides data on Kiadis Pharma’s international multi-center study, in which a total of 23 leukemia patients, including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), have been enrolled to be treated with ATIR101™ as part of their transplant regimen. In addition, the abstract includes a comparison to a historic control group. (more…)

Amsterdam, The Netherlands, October 20, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the first patient has been enrolled into its repeat-dosing Phase II clinical trial, CR-AIR-008, with its lead product ATIR101™. The patient was enrolled in Hamilton, Canada within a month of receiving regulatory approval for the study from the Canadian authorities. (more…)

Advisory Committee Meeting Scheduled for November 24, 2015

SAN RAFAEL, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (BMRN) today announced that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the New Drug Application (NDA) for drisapersen. The FDA is currently reviewing drisapersen for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The advisory committee will review drisapersen data included in a new drug application (NDA) during a meeting on November 24, 2015. (more…)

Amsterdam, The Netherlands, September 30, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approvals from the national authorities both in Canada and in Belgium to start a further Phase II clinical trial with its lead product ATIR101™. In this new trial the safety and efficacy of using a second dose of ATIR101™ will be studied (NCT02500550 / EudraCT 2015-002821-20). (more…)